Update: International report. Using pharmacoepidemiology to inform drug coverage policy: Initial lessons from a two-province collaborative

Health Affairs

Volumn 25, Issue 5, 2006, Pages 1436-1443

  Paterson, J Michael ^a   Laupacis, Andreas ^b   Bassett, Ken ^c   Anderson, Geoffrey M ^b  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b ICES ^*

^c Therapeutics Initiative   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANADA; COOPERATION; EVIDENCE BASED MEDICINE; HEALTH INSURANCE; HUMAN; PHARMACOEPIDEMIOLOGY; PUBLIC HEALTH;

BRITISH COLUMBIA; COOPERATIVE BEHAVIOR; EVIDENCE-BASED MEDICINE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; NATIONAL HEALTH PROGRAMS; ONTARIO; PHARMACOEPIDEMIOLOGY;

EID: 33749325474     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.25.5.1436     Document Type: Review

References (31)

1. R. Platt and A. Ommaya, " A Beneficial Side Effect of the Medicare Drug Benefit," New England Journal of Medicine 353, no. 26 (2005): 2742-2743;
2. N.E. Morden and S.D. Sullivan, "States' Control of Prescription Drug Spending: A Heterogeneous Approach," Health Affairs 24, no. 4 (2005): 1032-1038;
3. Centers for Medicare and Medicaid Services, "Medicare Prescription Drug Data Strategy: Improving Evidence for Patient Care through the Medicare Prescription Drug Benefit" (Baltimore, Md.: CMS, June 2005);
4. and CMS, "National Coverage Determinations with Data Collection as a Condition of Coverage: Coverage with Evidence Development," 12 July 2006, https://www.cms.hhs.gov/mcd/ncpc_view_document.asp?id=8 (accessed 14 July 2006).
5. S.G. Morgan et al., "Centralized Drug Review Processes in Australia, Canada, New Zealand, and the United Kingdom," Health Affairs 25, no. 2 (2006): 337-347;
6. and T. Stafinski and D. Menon, "A Comparison of International Models for Common Drug Review Processes in Publicly-Funded Health Care Systems," Working Paper no. 03-09, October 2003, http://www.ihe.ca/documents/ihe/ publications/papers/2003-09 paper.pdf (accessed 21 July 2006).
7. Canadian Coordinating Office for Health Technology Assessment, "Common Drug Review," 9 May 2006, http://www.cadth.ca/index.php/en/cdr (accessed 21 July 2006).
8. M. McMahon, S. Morgan, and C. Mitton, "The Common Drug Review: A NICE Start for Canada?" Health Policy 77, no. 3 (2006): 339-351.
9. B.L. Strom, Pharmacoepidemiology, 4th ed. (Toronto: John Wiley, 2005).
10. M. Maclure, R.S. Nakagawa, and B.C. Carleton, "Applying Research to the Policy Cycle: Implementing and Evaluating Evidence-based Drug Policies in British Columbia," in Informing Judgment: Case Studies of Health Policy and Research in Six Countries, September 2001, http://www.milbank.org/2001cochrane/ 010903cochrane.html#update (accessed 18 August 2004);
11. S. Schneeweiss et al., "Outcomes of Reference Pricing for Angiotensin-Converting-Enzyme Inhibitors," New England Journal of Medicine 346, no. 11 (2002): 822-829;
12. and S. Schneeweiss et al., "Clinical and Economic Consequences of a Reimbursement Restriction of Nebulised Respiratory Therapy in Adults: Direct Comparison of Randomised and Observational Evaluations," British Medical Journal 328, no. 7439 (2004): 560-566.
13. S. Morgan, K. Bassett, and B. Mintzes, "Outcomes-based Drug Coverage in British Columbia," Health Affairs 23, no. 3 (2004): 269-276.
14. S. Morgan, K. Bassett, and B. Mintzes, "Outcomes-based Drug Coverage in British Columbia," Health Affairs 23, no. 3 (2004): 269-276. Ibid.
15. A. Laupacis, "Inclusion of Drugs in Provincial Drug Benefit Programs: Who Is Making These Decisions, and Are They the Right Ones?" Canadian Medical Association Journal 166, no. 1 (2002): 44-47.
16. A. Laupacis et al., "Gaps in the Evaluation and Monitoring of New Pharmaceuticals: Proposal for a Different Approach," Canadian Medical Association Journal 169, no. 11 (2003): 1167-1170;
17. and Agency for Healthcare Research and Quality, "Effective Health Care: Projects in Progress," http://effectivehealthcare.ahrq.gov/decide/ activeDecide.cfm (accessed 23 February 2006).
18. R. West et al., " 'Cost-Effectiveness' Estimates Result in Flawed Decision-Making in Listing Drugs for Reimbursement," Canadian Journal of Public Health 93, no. 6 (2002): 421-425.
19. See, for example, M. Mamdani et al., Uptake and Outcomes Associated with Cyclooxygenase-2 (COX-2) Inhibitors in Ontario's Elderly, ICES Investigative Report, July 2005, http://www.ices.on.ca/file/COX2_Report_June%2030-05_2.pdf (accessed 26 May 2006);
20. M. Mamdani et al., "Observational Study of Upper Gastrointestinal Haemorrhage in Elderly Patients Given Selective Cyclo-Oxygenase-2 Inhibitors or Conventional Non-Steroidal Anti-Inflammatory Drugs," British Medical Journal 325, no. 7365 (2002): 624-630;
21. M. Mamdani et al., "Effect of Selective Cyclooxygenase 2 Inhibitors and Naproxen on Short-Term Risk of Acute Myocardial Infarction in the Elderly," Archives of Internal Medicine 163, no. 4 (2003): 481-486;
22. M. Mamdani et al., "Cyclo-Oxygenase-2 Inhibitors versus Non-Selective Non-Steroidal Anti-Inflammatory Drugs and Congestive Heart Failure Outcomes in Elderly Patients: A Population-based Cohort Study," Lancet 363, no. 9423 (2004): 1751-1756;
23. and M. Mamdani et al., "Gastrointestinal Bleeding after the Introduction of COX-2 Inhibitors: Ecological Study," British Medical Journal 328, no. 7453 (2004): 1415-1416.
24. A.R. Levy et al., "Coding Accuracy of Administrative Drug Claims in the Ontario Drug Benefit Database," Canadian Journal of Clinical Pharmacology 10, no. 2 (2003): 67-71.
25. Mamdani et al., "Uptake and Outcomes";
26. Mamdani et al., "Observational Study";
27. Mamdani et al., "Effect of Selective Cyclooxygenase 2 Inhibitors";
28. Mamdani et al., "Cyclo-oxygenase-2 Inhibitors";
29. and Mamdani et al., "Gastrointestinal Bleeding."
30. C.Y. Lu et al., "Access to High Cost Drugs in Australia," British Medical Journal 329, no. 7463 (2004): 415-416;
31. and S.G. Barr et al., "Mandatory Pharmacosurveillance - A Canadian Model for Access to Therapy and Research," Clinical and Experimental Rheumatology 22, no. 5, Supp. 35 (2004): S39-S43.